ribavirin has been researched along with Atherogenesis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Izumi, T; Kawagishi, N; Kimura, M; Kudo, Y; Maehara, O; Miyoshi, H; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Nishida, M; Ogawa, K; Ohara, M; Sakamoto, N; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Escolano, C; Gutiérrez, F; López, N; Masiá, M; Robledano, C | 1 |
2 other study(ies) available for ribavirin and Atherogenesis
| Article | Year |
|---|---|
Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
Topics: Adult; Aged; Antiviral Agents; Atherosclerosis; Cholesterol, LDL; Dyslipidemias; Fatty Liver; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lipid Metabolism; Liver; Male; Middle Aged; Ribavirin; Risk Factors; Sustained Virologic Response | 2018 |
Treatment for hepatitis C virus with pegylated interferon-α plus ribavirin induces anti-atherogenic effects on cardiovascular risk biomarkers in HIV-infected and -uninfected patients.
Topics: Adult; Antiviral Agents; Atherosclerosis; Biomarkers; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin | 2011 |